All In Biotech

Free tool

FAERS Monitor: Vyvgart Hytrulo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761304 or its brand name (Vyvgart Hytrulo, Efgartigimod Alfa and Hyaluronidase-Qvfc). Reports on generic versions are filed under their own applications.

Reports

485

Serious

426

88% of reports

Hospitalization

170

Death reported

23

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myasthenia gravis68
  • fatigue67
  • asthenia40
  • drug ineffective38
  • fall37
  • muscular weakness37
  • injection site erythema25
  • myasthenia gravis crisis25
  • condition aggravated24
  • headache24
  • injection site pain24
  • therapy change23
  • chronic inflammatory demyelinating polyradiculoneuropathy22
  • dyspnoea21
  • urinary tract infection21

Reports by year received

View as table
YearReports
20201
20222
202323
2024198
2025132
2026129

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,674 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravis crisisSignal25744.3506.417,523
chronic inflammatory demyelinating polyradiculoneuropathySignal22674.4446.913,913
myasthenia gravisSignal68368.2295.124,339
therapy changeSignal23101.768.22,189
muscular weaknessSignal3714.110.4440
injection site erythemaSignal258.76.0165
urinary tract infectionSignal215.33.570
fallSignal374.83.5110
astheniaSignal404.63.4112
fatigueSignal673.73.0136
condition aggravatedSignal243.42.339
injection site painSignal243.42.339
headache241.71.16
dyspnoea211.61.14
drug ineffective381.30.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.